# US 2014/0154682 A1 · Methods for non-invasive prenatal ploidy calling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154682 A1
- Document ID: US20140154682A1
- Status: Published application
- Kind: A1
- Application number: 14/080,656
- Filed: 2013-11-14
- Published: 2014-06-05
- Earliest claimed: 2009-09-30
- Assignees: Natera, Inc.
- Applicants: Natera, Inc.
- Inventors: Matthew Rabinowitz; Allison Ryan; George Gemelos; Milena Banjevic; Zachary Demko
- Web page: https://patentgrep.com/patent/US20140154682A1

## CPC

- G16B 20/10: Ploidy or copy number detection
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G06N 7/01: Probabilistic graphical models, e.g. probabilistic networks
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/16: Primer sets for multiplex assays
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS

## Abstract

Disclosed herein are methods for determining the copy number of a chromosome in a fetus in the context of non-invasive prenatal diagnosis. In an embodiment, the measured genetic data from a sample of genetic material that contains both fetal DNA and maternal DNA is analyzed, along with the genetic data from the biological parents of the fetus, and the copy number of the chromosome of interest is determined. In an embodiment, the maternal serum is measured using a single-nucleotide polymorphism (SNP) microarray, along with parental genomic data, and the determination of the chromosome copy number is used to make clinical decisions pertaining to the fetus.

## Claims

### Claim 1

A method for determining the number of copies of a chromosome or chromosome segment of interest in the genome of a gestating fetus, the method comprising:
obtaining measured genetic data at a plurality of loci on a chromosome or chromosome segment of interest in the a mixed sample of DNA comprising fetal DNA and maternal DNA;
determining, on a computer, a ratio of fetal to maternal DNA in the mixed sample from the measured genetic data;
creating a plurality of hypotheses specifying the number of copies of the chromosome or chromosome segment of interest in the fetus;
determining, on a computer, the probability of each of the hypotheses using the measured genetic data and the ratio of fetal to maternal DNA; and
selecting the hypothesis with the greatest probability, thereby determining the number of copies of the chromosome or chromosome segment of interest in the genome of the fetus.

### Claim 2 (depends on 1)

The method of claim 1, further comprising obtaining measured genetic data at the plurality of loci from genetic material from the mother and/or father of the fetus, wherein the probability of each of the hypotheses is determined using the measured genetic data of the mother and/or father, the measured genetic data of the mixed sample, and the ratio of fetal to maternal DNA.

### Claim 3 (depends on 1)

The method of claim 1, wherein the plurality of loci comprises (i) a plurality of SNPs from the chromosome or chromosome segment of interest and (ii) a plurality of SNPs from at least one chromosome or chromosome segment that is expected to be disomic in the fetus.

### Claim 4 (depends on 3)

The method of claim 3, wherein the method comprises:
obtaining genotypic measurements at each of the SNPs from genetic material from the mother and the father of the fetus;
using the genotypic data of the mother and father to determine parental contexts for each of the SNPs;
grouping the genotypic measurements of the mixed sample into the parental contexts;
using the grouped genotypic measurements from the at least one chromosome that is expected to be disomic to determine a platform response;
using the grouped genotypic measurements from the at least one chromosome that is expected to be disomic to determine a ratio of fetal to maternal DNA in the mixed sample;
using the determined platform response and the determined ratio to calculate expected SNP measurements for the set of SNPs in at least one parental context under each hypothesis; and
calculating, on a computer, the probability that each of the hypotheses is true from the platform response, the determined ratio, the grouped genotypic measurements of the mixed sample, and the expected SNP measurements for the at least one parental context.

### Claim 5 (depends on 1)

The method of claim 1, comprising:
estimating, on a computer, expected data for the mixed sample for the case where the chromosome or chromosome segment of interest is euploid;
estimating, on a computer, expected data for the mixed sample for the case where the chromosome or chromosome segment of interest is aneuploid using the ratio of fetal to maternal DNA in the mixed sample;
calculating, on a computer, (i) a data fit between the measured genetic data and the expected data for the euploid case and (ii) a data fit between the measured genetic data and the expected data for the aneuploid case; and
selecting the case for which the data fit is best, thereby determining whether the chromosome or chromosome segment of interest in the fetus is euploid or aneuploid.

### Claim 6 (depends on 1)

The method of claim 1, further comprising obtaining measured genetic data at the plurality of loci from genetic material from the mother and/or father of the fetus, wherein the expected data for the aneuploidy case is determined using the measured genetic data of the mother and/or father, the measured genetic data of the mixed sample, and the ratio of fetal to maternal DNA.

### Claim 7 (depends on 1)

The method of claim 1, comprises aggregating the measured data on the chromosome or chromosome segment of interest.

### Claim 8 (depends on 7)

The method of claim 7, wherein determining the number of copies of the chromosome or chromosome segment of interest in the genome of the fetus comprises comparing the aggregated value for the chromosome or chromosome segment of interest to the aggregated value for one or more chromosomes expected to be disomic.

### Claim 9 (depends on 1)

The method of claim 1, wherein determining the number of copies of the chromosome or chromosome segment of interest in the genome of the fetus comprises comparing the mean value for the measured data for the chromosome or chromosome segment of interest to the mean value for the measured data for one or more other chromosomes.

### Claim 10 (depends on 1)

The method of claim 1, comprising calculating a maximum likelihood estimate of the ratio of fetal to maternal DNA in the mixed sample, thereby determining the ratio of fetal to maternal DNA in the mixed sample.

### Claim 11 (depends on 1)

The method of claim 1, wherein determining the ratio of fetal to maternal DNA in the mixed sample comprises:
obtaining measured genetic data from the mixed sample by measuring the quantity of each allele at a plurality of polymorphic loci on at least one chromosome that is expected to be disomic in both the mother and the fetus;
estimating, on a computer, expected allele measurements in the mixed sample at the plurality of polymorphic loci on the at least one chromosome for possible ratios of fetal to maternal DNA;
calculating, on a computer, a relative probability of each of the possible ratios using the model and the measured quantity of each allele at the plurality of polymorphic loci from the mixed sample; and
selecting the possible ratio with the greatest probability, thereby determining the ratio of fetal to maternal DNA in the mixed sample.

### Claim 12 (depends on 11)

The method of claim 11, further comprising
obtaining measured genetic data from the mother by measuring the quantity of each allele at the plurality of polymorphic loci in genetic material from the mother;
optionally obtaining measured genetic data from the father of the fetus by measuring the quantity of each allele at the plurality of polymorphic loci in genetic material from the father; and
determining, on a computer, the ratio of fetal to maternal DNA in the mixed sample given the measured genetic data of the mixed sample, the measured genetic data of mother, and optionally the measured genetic data of the father.

### Claim 13 (depends on 11)

The method of claim 11, wherein the polymorphic loci comprise SNPs.

### Claim 14 (depends on 1)

The method of claim 1, wherein the ratio of fetal to maternal DNA in the mixed sample is determined by measuring the amount of an allele at one or more polymorphic loci in which the fetus has the allele and the mother does not have the allele.

### Claim 15 (depends on 1)

The method of claim 1, wherein the ratio of fetal to maternal DNA in the mixed sample is determined by:
identifying one or more polymorphic loci where the mother is homozygous for a first allele at the polymorphic locus; and
using the amount of the second allele in the mixed sample for each of the identified polymorphic loci to determine the ratio of fetal to maternal DNA in the mixed sample.

### Claim 16 (depends on 1)

The method of claim 1, wherein the ratio of fetal to maternal DNA in the mixed sample is determined by:
identifying one or more polymorphic loci where the mother is homozygous for a first allele at the polymorphic locus, and the father is (i) heterozygous for the first allele and a second allele or (ii) homozygous for a second allele at the polymorphic locus; and
using the amount of the second allele in the mixed sample for each of the identified polymorphic loci to determine the ratio of fetal to maternal DNA in the mixed sample.

### Claim 17 (depends on 1)

The method of claim 1, comprises measuring the difference in methylation between one or more maternal and fetal alleles.

### Claim 18 (depends on 1)

The method of claim 1, further comprising:
determining the likelihood that the fetal genome contains three copies of a chromosome or chromosome segment of interest using the ratio of fetal to maternal DNA in the mixed sample.

### Claim 19 (depends on 1)

The method of claim 1, wherein a confidence is computed for the determination of the number of copies of the chromosome or chromosome segment of interest in the genome of the target individual.

### Claim 20 (depends on 1)

The method of claim 1, wherein the ratio of fetal to maternal DNA in the mixed sample is determined for individual chromosomes.

### Claim 21 (depends on 1)

The method of claim 1, wherein the mixed sample is derived from maternal blood or maternal plasma.

### Claim 22 (depends on 1)

The method of claim 1, wherein the fetal DNA is free floating DNA found in maternal blood or serum.

### Claim 23 (depends on 1)

The method of claim 1, wherein the fetal DNA is nuclear DNA found in one or more cells from the fetus.

### Claim 24 (depends on 1)

The method of claim 1, wherein the step of obtaining measured genetic data is performed by measuring genetic material using a technique selected from the group consisting of padlock probes, circularizing probes, genotyping microarrays, SNP genotyping assays, chip based microarrays, bead based microarrays, other SNP microarrays, other genotyping methods, Sanger DNA sequencing, pyrosequencing, high throughput sequencing, reversible dye terminator sequencing, sequencing by ligation, sequencing by hybridization, other methods of DNA sequencing, other high throughput genotyping platforms, fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), array CGH, and combinations thereof.

### Claim 25 (depends on 1)

The method of claim 1, wherein the method further comprises taking a clinical action based on the determination of whether the fetus is euploid or aneuploid, wherein the clinical action is termination of a pregnancy.

### Claim 26 (depends on 1)

The method of claim 1, wherein the method further comprises performing amniocentesis or chorion villus biopsy.

### Claim 27 (depends on 1)

The method of claim 1 wherein the chromosome of interest is selected from the group consisting of chromosome 13, chromosome 18, chromosome 21, the X chromosome, the Y chromosome, and combinations thereof.

### Claim 28 (depends on 1)

The method of claim 1, wherein the step of determining whether the chromosome or chromosome segment of interest in the fetus is euploid or aneuploid is performed for the purpose of screening for a chromosomal condition selected from the group consisting of nullsomy, monosomy, disomy, uniparental disomy, euploidy, trisomy, matched trisomy, unmatched trisomy, maternal trisomy, paternal trisomy, tetrasomy, matched tetrasomy, unmatched tetrasomy, other aneuploidy, unbalanced translocation, balanced translocation, recombination, deletion, insertion, mosaicism, and combinations thereof.

### Claim 29 (depends on 1)

The method of claim 1, wherein the method comprises determining whether the fetus has Down syndrome, Klinefelters syndrome, Edwards syndrome, or Turner syndrome.

### Claim 30

A method for determining the number of copies of a chromosome or chromosome segment of interest in the genome of a gestating fetus, the method comprising:
obtaining measured genetic data at a plurality of loci on a chromosome or chromosome segment of interest in the a mixed sample of DNA comprising fetal DNA and maternal DNA;
determining, on a computer, a ratio of fetal to maternal DNA in the mixed sample from the measured genetic data;
determining, on a computer, the number of copies of the chromosome or chromosome segment of interest in the genome of the fetus using the measured genetic data; and
calculating, on a computer, a confidence for the determination of the number of copies of the chromosome or chromosome segment using the measured genetic data and the ratio of fetal to maternal DNA.
